Update on prolactinomas. Part 2: Treatment and management strategies

Journal of Clinical Neuroscience

Volumn 22, Issue 10, 2015, Pages 1568-1574

  Wong, Anni ^a,b   Eloy, Jean Anderson ^a,b,c   Couldwell, William T ^d   Liu, James K ^a,b,c  

^a NEUROLOGICAL INSTITUTE OF NEW JERSEY   (United States)

^b New Jersey Medical School   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonist; Endoscopic endonasal transsphenoidal surgery; Pituitary tumor; Prolactinomas; Radiosurgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PROLACTIN; TEMOZOLOMIDE; ERGOLINE DERIVATIVE;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FAINTNESS; GAMMA KNIFE RADIOSURGERY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; HYPOPITUITARISM; MEDICATION COMPLIANCE; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT INDICATION; TUMOR RECURRENCE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA; ADVERSE EFFECTS; BLOOD; COMPLICATION; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; NEUROENDOSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PITUITARY NEOPLASMS; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROCEDURES; RADIOSURGERY; SPHENOID SINUS;

BROMOCRIPTINE; DISEASE MANAGEMENT; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEUROENDOSCOPY; PITUITARY NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROLACTIN; PROLACTINOMA; RADIOSURGERY; SPHENOID SINUS;

EID: 84941168199     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2015.03.059     Document Type: Review

References (71)

1. M.P. Gillam, M.E. Molitch, G. Lombardi, and et al. Advances in the treatment of prolactinomas Endocr Rev 27 2006 485 534
2. J.K. Liu, and W.T. Couldwell Contemporary management of prolactinomas Neurosurg Focus 16 2004 E2
3. W.A. Mann Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach Eur J Clin Invest 41 2011 334 342
4. V.K. Prabhakar, and J.R. Davis Hyperprolactinaemia Best Pract Res Clin Obstet Gynaecol 22 2008 341 353
5. F.F. Casanueva, M.E. Molitch, J.A. Schlechte, and et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrinol 65 2006 265 273
6. M.E. Molitch Management of medically refractory prolactinoma J Neurooncol 117 2014 421 428
7. J.A. Schlechte Clinical practice. Prolactinoma N Engl J Med 349 2003 2035 2041
8. J.A. Schlechte Long-term management of prolactinomas J Clin Endocrinol Metab 92 2007 2861 2865
9. C.P. Hofstetter, B.J. Shin, L. Mubita, and et al. Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas Neurosurg Focus 30 2011 E10
10. H.E. Turner, C.B. Adams, and J.A. Wass Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? Eur J Endocrinol 140 1999 43 47
11. J.K. Liu, M.D. Krieger, A. Amar, W.T. Couldwell, and M.H. Weiss Prolactinomas 6th ed. A. Quinones-Hinojosa, Schmidek & Sweet operative neurosurgical techniques: indications, methods, and results 2012 Saunders Elsevier Philadelphia
12. I. Halperin Rabinovich, R. Camara Gomez, M. Garcia Mouriz, and et al. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia Endocrinol Nutr 60 2013 308 319
13. A. Colao Pituitary tumours: the prolactinoma Best Pract Res Clin Endocrinol Metab 2009 575 596
14. M. Kars, O.M. Dekkers, A.M. Pereira, and et al. Update in prolactinomas Neth J Med 68 2010 104 112
15. M. Rahmanian, H.A. Meybodi, B. Larijani, and et al. Giant prolactinoma: case report and review of literature J Diabetes Metab Disord 12 2013 3
16. J. Webster Clinical management of prolactinomas Baillieres Best Pract Res Clin Endocrinol Metab 13 1999 395 408
17. J.J. Pinzone, L. Katznelson, D.C. Danila, and et al. Primary medical therapy of micro- and macroprolactinomas in men J Clin Endocrinol Metab 85 2000 3053 3057
18. R. Zanettini, A. Antonini, G. Gatto, and et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 2007 39 46
19. N. Martin Prolactin disorders Medicine 37 2009 411 413
20. F. Bogazzi, L. Manetti, V. Raffaelli, and et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies J Endocrinol Invest 31 2008 1119 1123
21. F. Bogazzi, S. Buralli, L. Manetti, and et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia Int J Clin Pract 62 2008 1864 1869
22. S. Vallette, K. Serri, J. Rivera, and et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas Pituitary 12 2009 153 157
23. S. Vallette, K. Serri, and O. Serri Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8 2010 49 54
24. I. Shimon, C. Benbassat, and M. Hadani Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men Eur J Endocrinol 156 2007 225 231
25. D.M. Cook Long-term management of prolactinomas-use of long-acting dopamine agonists Rev Endocr Metab Disord 6 2005 15 21
26. T. Mancini, F.F. Casanueva, and A. Giustina Hyperprolactinemia and prolactinomas Endocrinol Metab Clin North Am 37 2008 67 99 viii
27. J. Webster, G. Piscitelli, A. Polli, and et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group N Engl J Med 331 1994 904 909
28. M.C. Oh, and M.K. Aghi Dopamine agonist-resistant prolactinomas J Neurosurg 114 2011 1369 1379
29. C.M. Ogilvie, and S.R. Milsom Dopamine agonists in the treatment of prolactinoma: are they still first choice? Intern Med J 41 2011 156 161
30. B.A. Laway, and S.A. Mir Pregnancy and pituitary disorders: challenges in diagnosis and management Indian J Endocrinol Metab 17 2013 996 1004
31. S. Melmed, F.F. Casanueva, A.R. Hoffman, and et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 2011 273 288
32. M.E. Molitch Prolactinoma in pregnancy Best Pract Res Clin Endocrinol Metab 25 2011 885 896
33. O.M. Dekkers, J. Lagro, P. Burman, and et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis J Clin Endocrinol Metab 95 2010 43 51
34. T.M. Barber, J. Kenjre, C. Garnett, and et al. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma Clin Endocrinol (Oxf) 2011 819 824
35. J. Kharlip, R. Salvatori, G. Yenokyan, and et al. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy J Clin Endocrinol Metab 94 2009 2428 2436
36. A. Colao, Sarno A. Di, P. Cappabiance, and et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia N Engl J Med 2003 2023 2033
37. P. Anagnostis, F. Andamidou, S.A. Polyzos, and et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience Pituitary 15 2012 25 29
38. A. Colao, A. Di Sarno, E. Guerra, and et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy Clin Endocrinol (Oxf) 67 2007 426 433
39. L. Vroonen, M.L. Jaffrain-Rea, P. Petrossians, and et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients Eur J Endocrinol 167 2012 651 662
40. L.A. Behan, M.S. Draman, C. Moran, and et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review Pituitary 14 2011 362 366
41. V. Vasilev, A.F. Daly, L. Vroonen, and et al. Resistant prolactinomas J Endocrinol Invest 34 2011 312 316
42. A. Di Sarno, M.L. Landi, P. Cappabianca, and et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy J Clin Endocrinol Metab 86 2001 5256 5261
43. B.C. Whitelaw, D. Dworakowska, N.W. Thomas, and et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas Clin Endocrinol (Oxf) 76 2012 877 886
44. J.K. Liu, J. Patel, and J.A. Eloy The role of temozolomide in the treatment of aggressive pituitary tumors J Clin Neurosci 22 2015 923 929
45. W.T. Couldwell, M.H. Weiss, and E.R. Laws Jr. Prolactinomas N Engl J Med 350 2004 1054 1057 [author reply 1054-7]
46. J. Kreutzer, R. Buslei, H. Wallaschofski, and et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients Eur J Endocrinol 158 2008 11 18
47. P. Nomikos, M. Buchfelder, and R. Fahlbusch Current management of prolactinomas J Neurooncol 54 2001 139 150
48. R. Fahlbusch, and M. Buchfelder Present status of neurosurgery in the treatment of prolactinomas Neurosurg Rev 8 1985 195 205
49. J.B. Tyrrell, K.R. Lamborn, L.T. Hannegan, and et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results Neurosurgery 44 1999 254 261 [discussion 261-3]
50. W.T. Couldwell, and M.H. Weiss Medical and surgical management of microprolactinoma Pituitary 7 2004 31 32
51. M. Babey, R. Sahli, I. Vajtai, and et al. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists Pituitary 14 2011 222 230
52. W.T. Couldwell, R.L. Rovit, and M.H. Weiss Role of surgery in the treatment of microprolactinomas Neurosurg Clin N Am 14 2003 89-92, vii
53. A.P. Amar, W.T. Couldwell, J.C. Chen, and et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery J Neurosurg 97 2002 307 314
54. M. Buchfelder, and S. Schlaffer Surgical treatment of pituitary tumours Best Pract Res Clin Endocrinol Metab 23 2009 677 692
55. H. Ikeda, K. Watanabe, T. Tominaga, and et al. Transsphenoidal microsurgical results of female patients with prolactinomas Clin Neurol Neurosurg 115 2013 1621 1625
56. F.M. Swords, J.P. Monson, G.M. Besser, and et al. Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy Eur J Endocrinol 161 2009 819 828
57. J.A. Jane Jr., M.L. Vance, C.J. Woodburn, and et al. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach Neurosurg Focus 14 2003 e12
58. M.C. Oh, S. Kunwar, L. Blevins, and et al. Medical versus surgical management of prolactinomas Neurosurg Clin N Am 23 2012 669 678
59. L. Leksell The stereotaxic method and radiosurgery of the brain Acta Chir Scand 102 1951 316 319
60. J.P. Sheehan, A. Niranjan, J.M. Sheehan, and et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium J Neurosurg 102 2005 678 691
61. F. Castinetti, M. Nagai, I. Morange, and et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas J Clin Endocrinol Metab 94 2009 3400 3407
62. W. Kim, C. Clelland, I. Yang, and et al. Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas Surg Neurol Int 3 2012 S79 S89
63. X. Liu, H. Kano, D. Kondziolka, and et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas Pituitary 16 2013 68 75
64. L. Pan, N. Zhang, E.M. Wang, and et al. Gamma knife radiosurgery as a primary treatment for prolactinomas J Neurosurg 93 2000 10 13
65. N. Pouratian, J. Sheehan, J. Jagannathan, and et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas Neurosurgery 59 2006 255 266 [discussion 255-66]
66. P.J. Wilson, J.R. Williams, and R.I. Smee Single-centre experience of stereotactic radiosurgery and fractionated stereotactic radiotherapy for prolactinomas with the linear accelerator J Med Imaging Radiat Oncol 59 2015 371 378
67. S. Tanaka, M.J. Link, P.D. Brown, and et al. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas World Neurosurg 74 2010 147 152
68. A.M. Landolt, and N. Lomax Gamma knife radiosurgery for prolactinomas J Neurosurg 93 2000 14 18
69. J.K. Liu, M.H. Schmidt, J.D. MacDonald, and et al. Hypophysial transposition (hypophysopexy) for radiosurgical treatment of pituitary tumors involving the cavernous sinus. Technical note Neurosurg Focus 14 2003 e11
70. P. Taussky, R. Kalra, J. Coppens, and et al. Endocrinological outcome after pituitary transposition (hypophysopexy) and adjuvant radiotherapy for tumors involving the cavernous sinus J Neurosurg 115 2011 55 62
71. W.T. Couldwell, J.M. Rosenow, R.L. Rovit, and et al. Hypophysopexy technique for radiosurgical treatment of cavernous sinus pituitary adenoma Pituitary 5 2002 169 173